Pop-Bio
Business Services · 11-50 Employees
View Company Info for Free
Overview
Phone Number
+44 1223620020Website
www.pop-bioimaging.comRevenue
<$5 MillionIndustry
About Pop-Bio
Pop-Bio Org Chart
Is Pop-Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Pop-Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Pop-Bio is spiking on competitors!
Click to see if Pop-Bio had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Pop-Bio launches new products
Website visits: Recent activity has been detected on your website
Check if Pop-Bio has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Pop-Bio has new funding data
Congratulate Masked Content for being promoted to Masked Content at Pop-Bio
Earning: See what the market has to say on Pop-Bio recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Pop-Bio
Compare insights from companies similar to Pop-Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Pop-Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Pop-Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Pop-Bio.
Pop-Bio Tech Stack
A closer look at the technologies used by Pop-Bio
Pop-Bio News & Media
POP Biotechnologies' SNAP Vaccine Platform Enters Large-Scale Phase III Clinical Trials for COVID-19
BUFFALO, N.Y., Sept. 20, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the commencement of two Phase 3 clinical studies of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics (KOSDAQ: 206650). EuCorVac-19 is a protein-based vaccine consisting of a vaccine antigen displayed on immunogenic nanoparticles, using POP BIO's spontaneous-nanoliposome antigen particle (SNAP) technology.POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as Part of Eubiologics' COVID-19 Vaccine Candidate, EuCorVac-19
BUFFALO, N.Y., Feb. 06, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a biopharmaceutical startup, announces the approval of the plan for a Phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19 is a protein-based vaccine consisting of Eubiologics' protein antigen, EulMT, in-licensed from Korea Instit
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pop-Bio
Pop-Bio Ltd is a company that operates in the Research & Development industry. It employs 10to19 people and has 1Mto5M of revenue.... Read More